Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Novo Nordisk shares on the NYSE rose over 5% in premarket trading Monday, reversing some losses from Friday’s plunge that ...

PERSPECTIVES: The resurgence of Y2K skin-baring fashion trends coincides with the rise of prescription weight loss drugs like ...

Pfizer, AstraZeneca, Amgen and several other drug developers aiming to join the weight-loss drug market, which is estimated ...

Novo Nordisk's shares recovered some ground on Monday after a 27% slump on Friday in response to an underwhelming set of results from a Phase III trial of its new weight-loss drug CagriSema, but ...

Investing.com -- Novo Nordisk (CSE: NOVOb ) shares jumped over 9% on Monday, despite the company’s disappointing results for ...

Eli Lilly (NYSE: LLY) soared more than 60% from the start of the year through its peak this summer, thanks to the company's ...

Novo Nordisk shares have plunged 20% amid the disappointing trial result of its latest weight-loss drug CagriSema. The fall ...

Already established as cornerstone therapies in diabetes and obesity, GLP-1 receptor agonists have now cracked into the ...

Unless you’ve been living under a rock, you know that weight-loss drugs are the talk of the town. GLP-1 drugs, in particular, ...

Starting January 1, the cost of the popular weight loss medication Wegovy will drop significantly in Israel—but only for its ...